PT  - JOURNAL ARTICLE
AU  - Michael A. Crouch
AU  - Ivan N. Mefford
AU  - Ekpedeme U. Wade
TI  - Proton Pump Inhibitor Therapy Associated with Lower Glycosylated Hemoglobin Levels in Type 2 Diabetes
AID  - 10.3122/jabfm.2012.01.100161
DP  - 2012 Jan 01
TA  - The Journal of the American Board of Family
                Medicine
PG  - 50--54
VI  - 25
IP  - 1
4099  - http://www.jabfm.org/content/25/1/50.short
4100  - http://www.jabfm.org/content/25/1/50.full
SO  - J Am Board Fam Med2012 Jan 01; 25
AB  - Introduction: Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump inhibitors (PPIs) as adjunctive therapy might improve diabetes control through increasing serum gastrin and fasting insulin levels. Methods: Electronic medical records in a family medicine residency program office practice were reviewed for 73 individuals with type 2 diabetes (not taking insulin), for whom PPIs were prescribed. Values for glycosylated hemoglobin (HbA1c) for periods of time when a PPI had been prescribed were compared with HbA1c levels for periods of time with no record of PPI prescribing or over-the-counter PPI use. Results: The mean HbA1c for patients not taking insulin was 7.11 during periods with recorded prescribing or over-the-counter use of PPIs, compared with 7.70 during periods without recorded PPI therapy (P = .001). Mean HbA1c for metformin monotherapy was not significantly different (6.81 with PPI vs. 7.10 without PPI; n = 16; P = .25). Mean HbA1c was significantly different for combination therapy that included metformin and/or sulfonylurea and/or giltazone (7.26 vs. 7.80; n = 27; P = .002). Conclusion: The observed association between PPI therapy and lower HbA1c levels suggests that PPIs may be useful as adjunctive therapy for type 2 diabetes.